Ormat Joins Solar Millennium in Tender for Ashalim Solar Thermal Plant

Ormat Technologies Inc. has announced that the company’s Israeli arm Ormat Systems Ltd. has entered into an MoU with the company Solar Millennium AG for forming a consortium towards participating in a tender for developing, constructing and operating a solar thermal energy plant located in Ashalim, Israel, with an overall 120 MW capacity, approximately.

Under the MoU, Ormat Technologies will be supplying the power block, construction and balance of plant services while Solar Millennium will be providing the technology needed for this solar field. Ormat Technologies will own 68% of this consortium while Solar Millennium will own 32%, approximately. Both the parties have passed the pre-qualification stages successfully while the companies were invited for submitting the bid.

This is a BOT (build, operate and transfer) tender with an approximate time period of 25 years while the land is provided and owned by the Government of Israel. The electricity produced from this plant will be fed into the energy grid of IEC (Israel Electric Corporation). Solar millennium happens to be a German stock company that specializes in the realization and development of the solar thermal plants, worldwide, while Ormat Technologies is engaged in the power business of recovered energy and geothermal energy.

Source: http://www.ormat.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.